Home News ‘Fine-tuned’ data from IMpower010 shows OS benefit for subset of patients

‘Fine-tuned’ data from IMpower010 shows OS benefit for subset of patients

72
0


September 08, 2022

1 min watch


Source/Disclosures

Source:

Healio Interviews


Disclosures:
Borghaei reports serving as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly, and Merck.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

At this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, one of the more talked about presentations was IMpower010.

Hossein Borghaei, DO, MS, chief of thoracic medical oncology, professor of hematology/oncology, co-director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn Chair in Thoracic Oncology at Fox Chase Cancer Center, spoke with Healio about the “fine-tuning” of data from the trial.

“We were hoping that the overall survival advantage would be a little bit stronger in most of the patients,” said. “But what we have right now is a subset of patients that might be benefitting, and obviously more data is going to be presented at subsequent conferences.”

References:

  • Felip E, et al. Abstract PL03.09. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Previous articleHTFC Innovation Award to be presented at HealthTech Innovation Days
Next articleHow to Prevent Germs With These Innovative Medical Scrubs